16.05.2025

Proacta SA with positive EBITDA in the first quarter of 2025

We are pleased to announce that the interim report for the first quarter of 2025 has been published. During this period, the company generated revenues of PLN 1,114,139.91, while significantly reducing operating costs. As a result, profitability improved significantly – EBITDA amounted to PLN 14,093.45, which represents a positive result at this level compared to the loss recorded in the same period of the previous year.

During the period under review, Proacta focused on the further development of the Dbam o Siebie platform, both in terms of technology and sales and marketing. The increase in user efficiency and engagement confirms the effectiveness of the strategy implemented.

In addition, the Company has secured new contracts and partnerships, including with the Bank Guarantee Fund, and has signed an agreement with the Medical Research Agency, which will have a significant impact on the further development of bioinformatics projects. In the opinion of the Management Board, these activities will have a positive impact on subsequent financial periods as early as 2025.

The full text of the report is available in the Investor Relations tab.